Lilly exits Rigel alliance, adding to RIPK1 scrap heap
BioSpace
Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug on one of these programs for central nervous sys
pharminent
April 22, 2026 (Last updated: April 22, 2026)
BioSpace
Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug on one of these programs for central nervous sys
